User login
Extended-release fluvoxamine for social anxiety disorder and OCD
Fluvoxamine extended-release formulation was FDA-approved to treat generalized social anxiety disorder (GSAD) and obsessive-compulsive disorder (OCD) because it demonstrated efficacy in reducing anxiety symptoms of these disorders in 3 clinical trials. The new formulation may benefit patients unable to tolerate the existing immediate-release form.
Clinical implications
Like other selective serotonin reuptake inhibitors (SSRIs), fluvoxamine alleviates symptoms of GSAD and OCD. The extended-release formulation allows the medication to be administered once daily (Table 1) and, according to the manufacturer, may reduce side effects and improve tolerability.
Many clinicians have prescribed immediate-release fluvoxamine once daily, and the efficacy and tolerability of the immediate- and extended-release formulations have not been compared in head-to-head trials. In addition, no studies have examined the efficacy of extended-release fluvoxamine in treating other psychiatric conditions.
Table 1
Extended-release fluvoxamine: Fast facts
Brand name: Luvox CR |
Class: Selective serotonin reuptake inhibitor |
Indication: Generalized social anxiety disorder and obsessive-compulsive disorder |
Approval date: February 29, 2008 |
Availability date: March 2008 |
Manufacturer: Jazz Pharmaceuticals |
Dosing forms: 100 mg and 150 mg extended-release capsules |
Recommended dose: Starting dose: 100 mg/d. Titrate in 50-mg/week increments until maximum therapeutic benefit is achieved. Maximum recommended dose: 300 mg/d |
How it works
Decreased serotonin levels are associated with GSAD and OCD. Fluvoxamine’s therapeutic effect is thought to be mediated through its specific serotonin reuptake inhibition in the CNS.1
The drug acts primarily on serotonin 2C receptors, with no reported significant affinity for histaminergic, adrenergic, muscarinic, or dopaminergic receptors.1 Fluvoxamine’s 1-sigma receptor antagonism is unique among SSRIs, and researchers have suggested that this may make fluvoxamine more effective than other SSRIs in treating anxious or delusional depression.2
The extended-release formulation uses a spheroidal oral drug absorption system, a proprietary technology that limits peak-to-trough variance for 24 hours.1 The manufacturer postulates that decreased plasma concentration variability will improve fluvoxamine’s tolerability.1
Pharmacokinetics
In a single-dose crossover study of 28 healthy subjects, the mean maximum concentration of drug (Cmax) for extended-release fluvoxamine was 38% lower than that of the immediate-release formulation, which may reduce the risk of adverse effects.1 Its relative bioavailability was 84%, and mean plasma half-life was 16.3 hours in male and female volunteers.1
Fluvoxamine is extensively metabolized in the liver, primarily through oxidative demethylation and deamination.1 Nine metabolites constitute 85% of the urinary excretion product; the main metabolite is fluvoxamine acid.1 Approximately 2% of fluvoxamine is excreted unchanged in urine. Administering extended-release fluvoxamine capsules with food does not appear to affect the drug’s absorption.1
Fluvoxamine is a potent inhibitor of the cytochrome P450 (CYP) 1A2 isoenzyme and also is believed to significantly inhibit CYP3A4, CYP2C9, CYP3A4, and CYP2C19. It is a relatively weak inhibitor of CYP2D6.1
Efficacy
The FDA based its approval of extended-release fluvoxamine on data from 3 clinical trials with positive outcomes: 2 for GSAD and 1 for OCD (Table 2).1,3-6
GSAD trials. In the first GSAD study—a randomized, double-blind, placebo-controlled, multicenter trial of 300 subjects with GSAD—participants were randomly assigned to receive extended-release fluvoxamine or placebo for 12 weeks.3 The extended-release fluvoxamine group started at 100 mg administered at night, with dosages titrated at 50 mg/week based on efficacy and tolerability to a maximum of 300 mg/d.1 Subjects in the extended-release fluvoxamine group demonstrated a statistically significant change in Liebowitz Social Anxiety Scale (LSAS) scores from baseline compared with those receiving placebo (P=0.02). Researchers observed similar results in secondary measures.
In an extension of this study, 112 subjects who demonstrated at least minimal improvement from extended-release fluvoxamine by week 12 continued the same dosing regimen for an additional 12 weeks. Investigators found the drug’s beneficial effects persisted to 24 weeks, although the magnitude of the effect decreased.4
A separate study using the same dosing regimen enrolled 279 adult patients in a 12-week, multicenter, randomized, placebo-controlled trial.5 The fluvoxamine-treated group showed statistically and clinically significant improvement:
- by week 4 on the LSAS and the Clinical Global Impression-Improvement (CGI-I) scale
- by week 6 on the Sheehan Disability Scale, Clinical Global Impression-Severity scale (CGI-S) and Patient Global Impression of Improvement (PGI) scale.5
OCD trial. Hollander et al6 conducted a 12-week, double-blind, placebo-controlled, flexible-dose, parallel multicenter trial of 253 adult patients with OCD.6 Compared with those receiving placebo, subjects treated with extended-release fluvoxamine, 100 to 300 mg/d, showed a statistically significant decrease in score on the Yale-Brown Obsessive Compulsive Scale (P=0.001).6 Analysis of the CGIS and CGI-I also revealed statistically significant improvement compared with placebo. The effect appeared to begin at week 2.
As did the GSAD studies, this study compared extended-release fluvoxamine with placebo and not with the immediate-release formulation. Although no additional studies have examined the efficacy of extended-release fluvoxamine in treating OCD and the drug has not been evaluated in pediatric patients, the manufacturer notes that the immediate-release formulation has been evaluated in 2 studies with adult OCD patients and 1 pediatric OCD study, all of which had positive results.1
Table 2
Fluvoxamine extended-release: What the evidence says
Study | Measures used | Results |
---|---|---|
Generalized social anxiety disorder | ||
Westenberg et al (2004)3 | LSAS, CGI-S, CGI-I, SDS, PGI | Fluvoxamine was significantly more effective than placebo in decreasing LSAS total score (primary measure) starting at week 4 and in improving SDS, CGI-S, and CGI-I (secondary measures) |
Stein et al (2003)4 | LSAS, CGI-S, CGI-I, SDS, PGI | Severity of illness on the CGI-S scale and disability on the SDS were significantly lower in the fluvoxamine group than in the placebo group; fluvoxamine-treated subjects had a numerically greater decrease in LSAS total scores than subjects treated with placebo |
Davidson et al (2004)5 | LSAS, CGI-G, SDS, CGI-S, PGI | Fluvoxamine produced statistically and clinically significant improvements in symptoms starting at week 4 on the LSAS and CGI-I and at week 6 on the SDS, CGI-S, and PGI |
Obsessive-compulsive disorder | ||
Hollander et al (2003)6 | YBOCS, CGI-S, CGI-I | Fluvoxamine was significantly more effective than placebo in decreasing YBOCS total score beginning at week 2 and in improving CGI-S and CGI-I scores |
LSAS: Liebowitz Social Anxiety Scale; SDS: Sheehan Disability Scale; CGI-S: Clinical Global Impression-Severity of illness; CGI-I: Clinical Global Impression-Improvement; PGI: Patient Global Impression of Improvement; YBOCS: Yale-Brown Obsessive Compulsive Scale |
Tolerability
In the 3 published trials of extended-release fluvoxamine, adverse event rates were similar and consistent with earlier studies of the immediate-release formulation. 1 The manufacturer considered adverse events likely to be drug-related if they had an incidence ≥5% and at least twice that of placebo (Table 3). 1, 3- 6
Adverse events caused 26% of patients in the GSAD studies and 19% in the OCD trial to discontinue treatment. No deaths, life-threatening adverse events, or suicide attempts were reported.3-6 No statistically significant differences in weight gain or loss, vital signs, laboratory findings, or ECG changes were found between patients treated with extended-release fluvoxamine and those receiving placebo.1
Table 3
Extended-release fluvoxamine: Adverse events*
Study | Adverse events |
---|---|
Both GSAD and OCD studies | Abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating, tremor |
GSAD studies only | Dyspepsia, dizziness, insomnia, yawning |
OCD study only | Accidental injury, anxiety, decreased libido, myalgia, pharyngitis, emesis |
* Includes events with an incidence ≥5% and at least twice that of placebo GSAD: generalized social anxiety disorder; OCD: obsessive-compulsive disorder | |
Source: References 3-6 |
Contraindications
Immediate- and extended-release fluvoxamine have the same active ingredient and therefore the same contraindications. Coadministration of alosetron, pimozide, thioridazine, or tizanidine, is contraindicated, as is using monoamine oxidase (MAO) inhibitors with extended-release fluvoxamine or within 14 days of discontinuing fluvoxamine treatment. Extended-release fluvoxamine has the same warnings that all SSRIs share regarding clinical worsening and suicide risk, administration to bipolar patients, neuroleptic malignant syndrome, serotonin syndrome, and possible increases in coagulation.1,2
The FDA classifies extended-release fluvoxamine as pregnancy category C.1 The drug is not contraindicated for lactating mothers, but because fluvoxamine is secreted in breast milk discuss with breast-feeding patients the benefits and risks of continuing fluvoxamine therapy.1 Infants exposed to immediate-release fluvoxamine in late pregnancy have developed serious adverse reactions, including respiratory distress, cyanosis, apnea, and seizures.1
Dosing
The recommended starting dose of extended-release fluvoxamine is 100 mg once daily, with or without food.1 The dose can be titrated in 50-mg/week increments as tolerated to achieve maximum therapeutic benefit, to the maximum recommended dose of 300 mg/d. Unlike immediate-release fluvoxamine, which is occasionally split into twice-daily doses, extended-release fluvoxamine must be administered only once daily, even at high doses.1,2
Related resource
- Luvox CR prescribing information. www.jazzpharmaceuticals.com/content/news/documents/LUVOX_CR.pdf.
Drug brand names
- Alosetron • Lotronex
- Fluvoxamine • Luvox
- Fluvoxamine extended-release • Luvox CR
- Pimozide • Orap
- Thioridazine • Mellaril
- Tizanidine • Zanaflex
Disclosures
Dr. Kuzma reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Black receives research/grant support from Forest Laboratories and is a consultant to Jazz Pharmaceuticals.
1. Luvox CR [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; 2008.
2. Stahl SM. Essential psychopharmacology: the prescriber’s guide. Revised and updated edition. New York, NY: Cambridge University Press; 2006.
3. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(1):49-55.
4. Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6(4):317-23.
5. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(2):118-25.
6. Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64(6):640-7.
Fluvoxamine extended-release formulation was FDA-approved to treat generalized social anxiety disorder (GSAD) and obsessive-compulsive disorder (OCD) because it demonstrated efficacy in reducing anxiety symptoms of these disorders in 3 clinical trials. The new formulation may benefit patients unable to tolerate the existing immediate-release form.
Clinical implications
Like other selective serotonin reuptake inhibitors (SSRIs), fluvoxamine alleviates symptoms of GSAD and OCD. The extended-release formulation allows the medication to be administered once daily (Table 1) and, according to the manufacturer, may reduce side effects and improve tolerability.
Many clinicians have prescribed immediate-release fluvoxamine once daily, and the efficacy and tolerability of the immediate- and extended-release formulations have not been compared in head-to-head trials. In addition, no studies have examined the efficacy of extended-release fluvoxamine in treating other psychiatric conditions.
Table 1
Extended-release fluvoxamine: Fast facts
Brand name: Luvox CR |
Class: Selective serotonin reuptake inhibitor |
Indication: Generalized social anxiety disorder and obsessive-compulsive disorder |
Approval date: February 29, 2008 |
Availability date: March 2008 |
Manufacturer: Jazz Pharmaceuticals |
Dosing forms: 100 mg and 150 mg extended-release capsules |
Recommended dose: Starting dose: 100 mg/d. Titrate in 50-mg/week increments until maximum therapeutic benefit is achieved. Maximum recommended dose: 300 mg/d |
How it works
Decreased serotonin levels are associated with GSAD and OCD. Fluvoxamine’s therapeutic effect is thought to be mediated through its specific serotonin reuptake inhibition in the CNS.1
The drug acts primarily on serotonin 2C receptors, with no reported significant affinity for histaminergic, adrenergic, muscarinic, or dopaminergic receptors.1 Fluvoxamine’s 1-sigma receptor antagonism is unique among SSRIs, and researchers have suggested that this may make fluvoxamine more effective than other SSRIs in treating anxious or delusional depression.2
The extended-release formulation uses a spheroidal oral drug absorption system, a proprietary technology that limits peak-to-trough variance for 24 hours.1 The manufacturer postulates that decreased plasma concentration variability will improve fluvoxamine’s tolerability.1
Pharmacokinetics
In a single-dose crossover study of 28 healthy subjects, the mean maximum concentration of drug (Cmax) for extended-release fluvoxamine was 38% lower than that of the immediate-release formulation, which may reduce the risk of adverse effects.1 Its relative bioavailability was 84%, and mean plasma half-life was 16.3 hours in male and female volunteers.1
Fluvoxamine is extensively metabolized in the liver, primarily through oxidative demethylation and deamination.1 Nine metabolites constitute 85% of the urinary excretion product; the main metabolite is fluvoxamine acid.1 Approximately 2% of fluvoxamine is excreted unchanged in urine. Administering extended-release fluvoxamine capsules with food does not appear to affect the drug’s absorption.1
Fluvoxamine is a potent inhibitor of the cytochrome P450 (CYP) 1A2 isoenzyme and also is believed to significantly inhibit CYP3A4, CYP2C9, CYP3A4, and CYP2C19. It is a relatively weak inhibitor of CYP2D6.1
Efficacy
The FDA based its approval of extended-release fluvoxamine on data from 3 clinical trials with positive outcomes: 2 for GSAD and 1 for OCD (Table 2).1,3-6
GSAD trials. In the first GSAD study—a randomized, double-blind, placebo-controlled, multicenter trial of 300 subjects with GSAD—participants were randomly assigned to receive extended-release fluvoxamine or placebo for 12 weeks.3 The extended-release fluvoxamine group started at 100 mg administered at night, with dosages titrated at 50 mg/week based on efficacy and tolerability to a maximum of 300 mg/d.1 Subjects in the extended-release fluvoxamine group demonstrated a statistically significant change in Liebowitz Social Anxiety Scale (LSAS) scores from baseline compared with those receiving placebo (P=0.02). Researchers observed similar results in secondary measures.
In an extension of this study, 112 subjects who demonstrated at least minimal improvement from extended-release fluvoxamine by week 12 continued the same dosing regimen for an additional 12 weeks. Investigators found the drug’s beneficial effects persisted to 24 weeks, although the magnitude of the effect decreased.4
A separate study using the same dosing regimen enrolled 279 adult patients in a 12-week, multicenter, randomized, placebo-controlled trial.5 The fluvoxamine-treated group showed statistically and clinically significant improvement:
- by week 4 on the LSAS and the Clinical Global Impression-Improvement (CGI-I) scale
- by week 6 on the Sheehan Disability Scale, Clinical Global Impression-Severity scale (CGI-S) and Patient Global Impression of Improvement (PGI) scale.5
OCD trial. Hollander et al6 conducted a 12-week, double-blind, placebo-controlled, flexible-dose, parallel multicenter trial of 253 adult patients with OCD.6 Compared with those receiving placebo, subjects treated with extended-release fluvoxamine, 100 to 300 mg/d, showed a statistically significant decrease in score on the Yale-Brown Obsessive Compulsive Scale (P=0.001).6 Analysis of the CGIS and CGI-I also revealed statistically significant improvement compared with placebo. The effect appeared to begin at week 2.
As did the GSAD studies, this study compared extended-release fluvoxamine with placebo and not with the immediate-release formulation. Although no additional studies have examined the efficacy of extended-release fluvoxamine in treating OCD and the drug has not been evaluated in pediatric patients, the manufacturer notes that the immediate-release formulation has been evaluated in 2 studies with adult OCD patients and 1 pediatric OCD study, all of which had positive results.1
Table 2
Fluvoxamine extended-release: What the evidence says
Study | Measures used | Results |
---|---|---|
Generalized social anxiety disorder | ||
Westenberg et al (2004)3 | LSAS, CGI-S, CGI-I, SDS, PGI | Fluvoxamine was significantly more effective than placebo in decreasing LSAS total score (primary measure) starting at week 4 and in improving SDS, CGI-S, and CGI-I (secondary measures) |
Stein et al (2003)4 | LSAS, CGI-S, CGI-I, SDS, PGI | Severity of illness on the CGI-S scale and disability on the SDS were significantly lower in the fluvoxamine group than in the placebo group; fluvoxamine-treated subjects had a numerically greater decrease in LSAS total scores than subjects treated with placebo |
Davidson et al (2004)5 | LSAS, CGI-G, SDS, CGI-S, PGI | Fluvoxamine produced statistically and clinically significant improvements in symptoms starting at week 4 on the LSAS and CGI-I and at week 6 on the SDS, CGI-S, and PGI |
Obsessive-compulsive disorder | ||
Hollander et al (2003)6 | YBOCS, CGI-S, CGI-I | Fluvoxamine was significantly more effective than placebo in decreasing YBOCS total score beginning at week 2 and in improving CGI-S and CGI-I scores |
LSAS: Liebowitz Social Anxiety Scale; SDS: Sheehan Disability Scale; CGI-S: Clinical Global Impression-Severity of illness; CGI-I: Clinical Global Impression-Improvement; PGI: Patient Global Impression of Improvement; YBOCS: Yale-Brown Obsessive Compulsive Scale |
Tolerability
In the 3 published trials of extended-release fluvoxamine, adverse event rates were similar and consistent with earlier studies of the immediate-release formulation. 1 The manufacturer considered adverse events likely to be drug-related if they had an incidence ≥5% and at least twice that of placebo (Table 3). 1, 3- 6
Adverse events caused 26% of patients in the GSAD studies and 19% in the OCD trial to discontinue treatment. No deaths, life-threatening adverse events, or suicide attempts were reported.3-6 No statistically significant differences in weight gain or loss, vital signs, laboratory findings, or ECG changes were found between patients treated with extended-release fluvoxamine and those receiving placebo.1
Table 3
Extended-release fluvoxamine: Adverse events*
Study | Adverse events |
---|---|
Both GSAD and OCD studies | Abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating, tremor |
GSAD studies only | Dyspepsia, dizziness, insomnia, yawning |
OCD study only | Accidental injury, anxiety, decreased libido, myalgia, pharyngitis, emesis |
* Includes events with an incidence ≥5% and at least twice that of placebo GSAD: generalized social anxiety disorder; OCD: obsessive-compulsive disorder | |
Source: References 3-6 |
Contraindications
Immediate- and extended-release fluvoxamine have the same active ingredient and therefore the same contraindications. Coadministration of alosetron, pimozide, thioridazine, or tizanidine, is contraindicated, as is using monoamine oxidase (MAO) inhibitors with extended-release fluvoxamine or within 14 days of discontinuing fluvoxamine treatment. Extended-release fluvoxamine has the same warnings that all SSRIs share regarding clinical worsening and suicide risk, administration to bipolar patients, neuroleptic malignant syndrome, serotonin syndrome, and possible increases in coagulation.1,2
The FDA classifies extended-release fluvoxamine as pregnancy category C.1 The drug is not contraindicated for lactating mothers, but because fluvoxamine is secreted in breast milk discuss with breast-feeding patients the benefits and risks of continuing fluvoxamine therapy.1 Infants exposed to immediate-release fluvoxamine in late pregnancy have developed serious adverse reactions, including respiratory distress, cyanosis, apnea, and seizures.1
Dosing
The recommended starting dose of extended-release fluvoxamine is 100 mg once daily, with or without food.1 The dose can be titrated in 50-mg/week increments as tolerated to achieve maximum therapeutic benefit, to the maximum recommended dose of 300 mg/d. Unlike immediate-release fluvoxamine, which is occasionally split into twice-daily doses, extended-release fluvoxamine must be administered only once daily, even at high doses.1,2
Related resource
- Luvox CR prescribing information. www.jazzpharmaceuticals.com/content/news/documents/LUVOX_CR.pdf.
Drug brand names
- Alosetron • Lotronex
- Fluvoxamine • Luvox
- Fluvoxamine extended-release • Luvox CR
- Pimozide • Orap
- Thioridazine • Mellaril
- Tizanidine • Zanaflex
Disclosures
Dr. Kuzma reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Black receives research/grant support from Forest Laboratories and is a consultant to Jazz Pharmaceuticals.
Fluvoxamine extended-release formulation was FDA-approved to treat generalized social anxiety disorder (GSAD) and obsessive-compulsive disorder (OCD) because it demonstrated efficacy in reducing anxiety symptoms of these disorders in 3 clinical trials. The new formulation may benefit patients unable to tolerate the existing immediate-release form.
Clinical implications
Like other selective serotonin reuptake inhibitors (SSRIs), fluvoxamine alleviates symptoms of GSAD and OCD. The extended-release formulation allows the medication to be administered once daily (Table 1) and, according to the manufacturer, may reduce side effects and improve tolerability.
Many clinicians have prescribed immediate-release fluvoxamine once daily, and the efficacy and tolerability of the immediate- and extended-release formulations have not been compared in head-to-head trials. In addition, no studies have examined the efficacy of extended-release fluvoxamine in treating other psychiatric conditions.
Table 1
Extended-release fluvoxamine: Fast facts
Brand name: Luvox CR |
Class: Selective serotonin reuptake inhibitor |
Indication: Generalized social anxiety disorder and obsessive-compulsive disorder |
Approval date: February 29, 2008 |
Availability date: March 2008 |
Manufacturer: Jazz Pharmaceuticals |
Dosing forms: 100 mg and 150 mg extended-release capsules |
Recommended dose: Starting dose: 100 mg/d. Titrate in 50-mg/week increments until maximum therapeutic benefit is achieved. Maximum recommended dose: 300 mg/d |
How it works
Decreased serotonin levels are associated with GSAD and OCD. Fluvoxamine’s therapeutic effect is thought to be mediated through its specific serotonin reuptake inhibition in the CNS.1
The drug acts primarily on serotonin 2C receptors, with no reported significant affinity for histaminergic, adrenergic, muscarinic, or dopaminergic receptors.1 Fluvoxamine’s 1-sigma receptor antagonism is unique among SSRIs, and researchers have suggested that this may make fluvoxamine more effective than other SSRIs in treating anxious or delusional depression.2
The extended-release formulation uses a spheroidal oral drug absorption system, a proprietary technology that limits peak-to-trough variance for 24 hours.1 The manufacturer postulates that decreased plasma concentration variability will improve fluvoxamine’s tolerability.1
Pharmacokinetics
In a single-dose crossover study of 28 healthy subjects, the mean maximum concentration of drug (Cmax) for extended-release fluvoxamine was 38% lower than that of the immediate-release formulation, which may reduce the risk of adverse effects.1 Its relative bioavailability was 84%, and mean plasma half-life was 16.3 hours in male and female volunteers.1
Fluvoxamine is extensively metabolized in the liver, primarily through oxidative demethylation and deamination.1 Nine metabolites constitute 85% of the urinary excretion product; the main metabolite is fluvoxamine acid.1 Approximately 2% of fluvoxamine is excreted unchanged in urine. Administering extended-release fluvoxamine capsules with food does not appear to affect the drug’s absorption.1
Fluvoxamine is a potent inhibitor of the cytochrome P450 (CYP) 1A2 isoenzyme and also is believed to significantly inhibit CYP3A4, CYP2C9, CYP3A4, and CYP2C19. It is a relatively weak inhibitor of CYP2D6.1
Efficacy
The FDA based its approval of extended-release fluvoxamine on data from 3 clinical trials with positive outcomes: 2 for GSAD and 1 for OCD (Table 2).1,3-6
GSAD trials. In the first GSAD study—a randomized, double-blind, placebo-controlled, multicenter trial of 300 subjects with GSAD—participants were randomly assigned to receive extended-release fluvoxamine or placebo for 12 weeks.3 The extended-release fluvoxamine group started at 100 mg administered at night, with dosages titrated at 50 mg/week based on efficacy and tolerability to a maximum of 300 mg/d.1 Subjects in the extended-release fluvoxamine group demonstrated a statistically significant change in Liebowitz Social Anxiety Scale (LSAS) scores from baseline compared with those receiving placebo (P=0.02). Researchers observed similar results in secondary measures.
In an extension of this study, 112 subjects who demonstrated at least minimal improvement from extended-release fluvoxamine by week 12 continued the same dosing regimen for an additional 12 weeks. Investigators found the drug’s beneficial effects persisted to 24 weeks, although the magnitude of the effect decreased.4
A separate study using the same dosing regimen enrolled 279 adult patients in a 12-week, multicenter, randomized, placebo-controlled trial.5 The fluvoxamine-treated group showed statistically and clinically significant improvement:
- by week 4 on the LSAS and the Clinical Global Impression-Improvement (CGI-I) scale
- by week 6 on the Sheehan Disability Scale, Clinical Global Impression-Severity scale (CGI-S) and Patient Global Impression of Improvement (PGI) scale.5
OCD trial. Hollander et al6 conducted a 12-week, double-blind, placebo-controlled, flexible-dose, parallel multicenter trial of 253 adult patients with OCD.6 Compared with those receiving placebo, subjects treated with extended-release fluvoxamine, 100 to 300 mg/d, showed a statistically significant decrease in score on the Yale-Brown Obsessive Compulsive Scale (P=0.001).6 Analysis of the CGIS and CGI-I also revealed statistically significant improvement compared with placebo. The effect appeared to begin at week 2.
As did the GSAD studies, this study compared extended-release fluvoxamine with placebo and not with the immediate-release formulation. Although no additional studies have examined the efficacy of extended-release fluvoxamine in treating OCD and the drug has not been evaluated in pediatric patients, the manufacturer notes that the immediate-release formulation has been evaluated in 2 studies with adult OCD patients and 1 pediatric OCD study, all of which had positive results.1
Table 2
Fluvoxamine extended-release: What the evidence says
Study | Measures used | Results |
---|---|---|
Generalized social anxiety disorder | ||
Westenberg et al (2004)3 | LSAS, CGI-S, CGI-I, SDS, PGI | Fluvoxamine was significantly more effective than placebo in decreasing LSAS total score (primary measure) starting at week 4 and in improving SDS, CGI-S, and CGI-I (secondary measures) |
Stein et al (2003)4 | LSAS, CGI-S, CGI-I, SDS, PGI | Severity of illness on the CGI-S scale and disability on the SDS were significantly lower in the fluvoxamine group than in the placebo group; fluvoxamine-treated subjects had a numerically greater decrease in LSAS total scores than subjects treated with placebo |
Davidson et al (2004)5 | LSAS, CGI-G, SDS, CGI-S, PGI | Fluvoxamine produced statistically and clinically significant improvements in symptoms starting at week 4 on the LSAS and CGI-I and at week 6 on the SDS, CGI-S, and PGI |
Obsessive-compulsive disorder | ||
Hollander et al (2003)6 | YBOCS, CGI-S, CGI-I | Fluvoxamine was significantly more effective than placebo in decreasing YBOCS total score beginning at week 2 and in improving CGI-S and CGI-I scores |
LSAS: Liebowitz Social Anxiety Scale; SDS: Sheehan Disability Scale; CGI-S: Clinical Global Impression-Severity of illness; CGI-I: Clinical Global Impression-Improvement; PGI: Patient Global Impression of Improvement; YBOCS: Yale-Brown Obsessive Compulsive Scale |
Tolerability
In the 3 published trials of extended-release fluvoxamine, adverse event rates were similar and consistent with earlier studies of the immediate-release formulation. 1 The manufacturer considered adverse events likely to be drug-related if they had an incidence ≥5% and at least twice that of placebo (Table 3). 1, 3- 6
Adverse events caused 26% of patients in the GSAD studies and 19% in the OCD trial to discontinue treatment. No deaths, life-threatening adverse events, or suicide attempts were reported.3-6 No statistically significant differences in weight gain or loss, vital signs, laboratory findings, or ECG changes were found between patients treated with extended-release fluvoxamine and those receiving placebo.1
Table 3
Extended-release fluvoxamine: Adverse events*
Study | Adverse events |
---|---|
Both GSAD and OCD studies | Abnormal ejaculation, anorexia, anorgasmia, asthenia, diarrhea, nausea, somnolence, sweating, tremor |
GSAD studies only | Dyspepsia, dizziness, insomnia, yawning |
OCD study only | Accidental injury, anxiety, decreased libido, myalgia, pharyngitis, emesis |
* Includes events with an incidence ≥5% and at least twice that of placebo GSAD: generalized social anxiety disorder; OCD: obsessive-compulsive disorder | |
Source: References 3-6 |
Contraindications
Immediate- and extended-release fluvoxamine have the same active ingredient and therefore the same contraindications. Coadministration of alosetron, pimozide, thioridazine, or tizanidine, is contraindicated, as is using monoamine oxidase (MAO) inhibitors with extended-release fluvoxamine or within 14 days of discontinuing fluvoxamine treatment. Extended-release fluvoxamine has the same warnings that all SSRIs share regarding clinical worsening and suicide risk, administration to bipolar patients, neuroleptic malignant syndrome, serotonin syndrome, and possible increases in coagulation.1,2
The FDA classifies extended-release fluvoxamine as pregnancy category C.1 The drug is not contraindicated for lactating mothers, but because fluvoxamine is secreted in breast milk discuss with breast-feeding patients the benefits and risks of continuing fluvoxamine therapy.1 Infants exposed to immediate-release fluvoxamine in late pregnancy have developed serious adverse reactions, including respiratory distress, cyanosis, apnea, and seizures.1
Dosing
The recommended starting dose of extended-release fluvoxamine is 100 mg once daily, with or without food.1 The dose can be titrated in 50-mg/week increments as tolerated to achieve maximum therapeutic benefit, to the maximum recommended dose of 300 mg/d. Unlike immediate-release fluvoxamine, which is occasionally split into twice-daily doses, extended-release fluvoxamine must be administered only once daily, even at high doses.1,2
Related resource
- Luvox CR prescribing information. www.jazzpharmaceuticals.com/content/news/documents/LUVOX_CR.pdf.
Drug brand names
- Alosetron • Lotronex
- Fluvoxamine • Luvox
- Fluvoxamine extended-release • Luvox CR
- Pimozide • Orap
- Thioridazine • Mellaril
- Tizanidine • Zanaflex
Disclosures
Dr. Kuzma reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Black receives research/grant support from Forest Laboratories and is a consultant to Jazz Pharmaceuticals.
1. Luvox CR [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; 2008.
2. Stahl SM. Essential psychopharmacology: the prescriber’s guide. Revised and updated edition. New York, NY: Cambridge University Press; 2006.
3. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(1):49-55.
4. Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6(4):317-23.
5. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(2):118-25.
6. Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64(6):640-7.
1. Luvox CR [package insert]. Palo Alto, CA: Jazz Pharmaceuticals; 2008.
2. Stahl SM. Essential psychopharmacology: the prescriber’s guide. Revised and updated edition. New York, NY: Cambridge University Press; 2006.
3. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(1):49-55.
4. Stein DJ, Westenberg HG, Yang H, et al. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6(4):317-23.
5. Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24(2):118-25.
6. Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64(6):640-7.
Compulsive shopping: When spending begins to consume the consumer
Ms. A has been compulsively shopping and spending since age 19 when she first obtained credit cards. After years of intense urges to shop and remorse over the financial consequences, she seeks psychiatric help. Now age 37 and divorced, she has controlled her spending only for two 1- to 2-year periods that coincided with bankruptcy proceedings.
With easy access to credit, many persons such as Ms. A develop what is variously called compulsive buying, compulsive shopping, addictive shopping, or shopaholism. Although “medicalizing” excessive shopping may seem to obscure its broader cultural and social causes,1 increasing evidence points to a discrete shopping disorder.
Our group has contributed to compulsive buying research and continues to evaluate potential treatments. We offer evidence and practical advice to help you:
- identify compulsive shopping disorder using the patient’s history and three screening questions
- differentiate compulsive shopping from manic or hypomanic shopping sprees
- educate patients about four steps to control compulsive shopping.
Table 1
Compulsive shopping disorder’s clinical signs
Onset in late adolescence to early adulthood |
Female-to-male ratio may be 9:1 |
Behaviors include shopping frequently, spending inappropriately, and fantasizing about future purchases |
Psychiatric comorbidity—mood disorders, substance abuse, eating disorders—is common among patients and first-degree relatives |
Chronic symptoms wax and wane, with widely varying severity |
Irresistible urges prompt spending by some patients |
Shopping is intensely exciting, with transitory feelings of happiness and power |
Feelings of distress and guilt develop after shopping; patients often hide purchases |
Patients may be in denial or feel embarrassed to disclose symptoms |
An Evolving Picture
Ms. A says shopping is her primary social activity and entertainment. Though she works full time, she shops three or more times a week, cruising expensive department stores and discount outlets on evenings and weekends. She buys clothing, shoes, makeup, jewelry, antiques, household electronics, and other items.
She says her shopping is spontaneous and impulsive. Shopping gives her an emotional “rush” that is frequently followed by periods of guilt, and she often returns or gives away purchased items. She is disappointed at her inability to control her shopping behavior and ashamed of the financial crises she has caused.
Compulsive buying is characterized by persistent or poorly controlled preoccupations, urges, or behaviors regarding shopping or spending, leading to adverse consequences.2 Onset in late adolescence to early adulthood is the usual pattern, and the disorder is thought to be chronic or recurrent. It is not listed in DSM-IV-TR but is considered an example of an impulse control disorder not otherwise specified. For this paper, we use the terms compulsive shopping and compulsive buying interchangeably.
The disorder’s tentative classification reflects debate about its conceptualization. Some clinicians and researchers consider compulsive buying an addiction similar to drug or alcohol misuse; others have linked it to depression or anxiety. Hollander3 and others have commented on its similarities with obsessive-compulsive disorder (OCD), and a recent study noted that compulsive buying is more common in patients with OCD than in matched controls.4 Still others—drawing on Kraepelin’s and Bleuler’s early work—consider compulsive buying an impulse control disorder, having features in common with pathological gambling and kleptomania.5
Prevalence. One survey estimates 2% to 8% of U.S. adults meet criteria for a compulsive shopping disorder, and community-based and clinical surveys suggest that 86% to 95% of them are women.5 The reported gender difference may be artifactual; women readily acknowledge that they enjoy shopping, whereas men are more likely to report that they “collect.”
Behavior patterns. No careful, longitudinal studies have examined compulsive buying disorder, but case reports suggest the condition is chronic, with a waxing and waning course and wide variance in symptom severity. In 20 consecutive patients with compulsive buying symptoms, one-half reported that irresistible urges prompted spending and three-quarters preferred to shop alone.6
Compulsive shoppers tend to shop frequently and spend inappropriately:
- at department and discount stores, specialty shops, and boutiques
- from mail order, television, and online merchants.
While shopping, compulsive shoppers may report feeling intensely excited, happy, and powerful. These emotions are frequently followed by distress or guilt. They may return purchases or hide them in closets or attics, never to be used.
Low-income persons who shop compulsively may do so at consignment shops or garage sales. In one of our studies, the most severe compulsive buyers had the lowest incomes,6 suggesting that:
- lack of money does not prevent compulsive shopping disorder from developing
- severe compulsive shoppers lack the ability to delay their shopping.
Psychiatric comorbidity
Compulsive buyers differ from matched controls when dimensional scales are used to measure psychopathology. One study found that compulsive buyers had elevated scores on the Beck Depression Inventory, the Spielberger Trait Anxiety Scale, and the Maudsley Obsessive Compulsive Inventory.2
Compulsive buyers and their first-degree relatives often have comorbid psychiatric disorders, particularly mood, anxiety, substance use, and eating disorders.5 Axis II disorders are also common; no particular type predominates, but the obsessive-compulsive, borderline, and avoidant personality types are seen most frequently.
McElroy et al7 defined compulsive buying disorder as:
- uncontrollable
- markedly distressing, time-consuming, and/or resulting in family, social, vocational, and/or financial difficulties
- not occurring only in the context of hypomanic or manic symptoms.
In a larger controlled study, our group8 compared 33 individuals who met the McElroy et al criteria for compulsive buying disorder and 22 control patients. The 137 first-degree relatives of the compulsive shoppers were significantly more likely than the controls’ relatives to have histories of depression, alcoholism, substance use, or multiple psychiatric diagnoses (as measured by the Family History Research Diagnostic Criteria).
Identifying a patient’s psychiatric comorbidities can help you develop:
- a biopsychosocial counseling plan—such as for a patient with borderline personality disorder who shops to relieve tension from relationship stress
- pharmacologic treatment strategies—such as prescribing a selective serotonin reuptake inhibitor (SSRI) for patients with comorbid major depression.
Manic versus compulsive behavior
Manic and hypomanic symptoms may be associated with impulsive and reckless spending. Thus, when evaluating excessive spending, always carefully evaluate patients for bipolar disorder.
Bipolar mania and excessive spending related to a compulsive buying disorder are relatively easy to differentiate:
- The manic patient’s unrestrained spending sprees correspond to manic episodes and are accompanied by euphoric mood, grandiosity, unrealistic plans, and often a giddy, overly bright affect.
- The compulsive shopper’s spending occurs year-round in a pattern suggesting ongoing preoccupation.
Not so for the manic, who may boast of his or her spending, display the evidence, and try to convince family and friends that the purchase is necessary or fits into some grandiose scheme. “Who doesn’t need two BMWs?” a manic patient said to one of the authors [DWB].
Screening and diagnosis
As with any psychiatric disorder, gathering an accurate history through a careful interview is important. This can be challenging with compulsive shopping disorder, however, because the patient may minimize symptoms out of embarrassment or denial. Your goal is to identify the shopping problem through nonjudgmental inquiries.
Diagnostic instruments. Researchers use assessment tools such as Faber and O’Guinn’s 7-item Compulsive Buying Scale9 to help diagnose this disorder. Our group developed a shopping version of the Yale-Brown Obsessive Compulsive Scale (YBOCS-SV) to help rate severity and change during clinical trials.10
Formal instruments may help in the clinical setting, but you can often elicit compulsive buying symptoms with a few screening questions (Table 2). If screening indicates a positive response, move to more detailed questions about:
- frequency of excessive shopping
- time spent shopping
- factors that trigger or worsen the shopping behavior
- amount of money spent.
Table 2
Is your patient a compulsive shopper? Ask these screening questions
Do you feel preoccupied with shopping and spending? |
Do you ever feel that your shopping behavior is excessive, inappropriate, or uncontrolled? |
Have your shopping desires, urges, fantasies, or behaviors ever:
|
Source: Black DW. Assessment of compulsive buying. In: Benson AL, ed. I shop, therefore I am: Compulsive buying and the search for self. Northvale, NJ: Jason Aronson; 2000:191-216. |
Stopping uncontrolled shopping
Compulsive shopping has no standard treatment, but evidence shows benefit from some SSRIs and psychotherapies.
Fluvoxamine. An early case series suggested antidepressants could curb compulsive buying,5 but later research has yielded mixed results.
Ms. A entered an experimental drug trial. She was randomly assigned to receive fluvoxamine and—despite difficulties with oversedation—tolerated a sustained dosage of 100 mg/d. After the 9-week trial, Ms. A said she thought less frequently about shopping, felt less compulsion to shop, and was spending less money and time shopping.
This open-label trial we conducted indicated that fluvoxamine, up to 300 mg/d, could be an effective treatment for compulsive buying.11 Two subsequent randomized controlled trials, however, found fluvoxamine did no better than placebo when treating compulsive shoppers.12,13
Citalopram. In an open-label trial,14 23 women and 1 man who met diagnostic criteria for compulsive shopping disorder (YBOCS-SV scores ≥17) received citalopram for 7 weeks. Dosages started at 20 mg/d and were increased as tolerated to 60 mg/d. Fifteen patients (63%) met response criteria—“much improved” or “very much improved” as measured by the Clinical Global Impressions-Improvement scale and a ≥50% decrease in YBOCS-SV score. Three patients (13%) discontinued treatment because of adverse effects (headache, rash, insomnia).
The 15 responders were then enrolled in a 9-week double-blind, placebo-controlled trial. Compulsive shopping symptoms recurred in 5 of 8 patients (63%) assigned to placebo, compared with none of the 7 who continued taking citalopram.
By comparison, escitalopram, 10 to 20 mg/d, showed little effect for compulsive shopping symptoms in an identically designed discontinuation trial by the same investigators. During the 7-week, open-label trial, 19 of 26 patients met response criteria. In the 9-week double-blind, controlled phase, however, 63% of initial responders relapsed while taking escitalopram, compared with 67% of those randomized to placebo.15
A naturalistic follow-up study of 24 patients treated with citalopram, 20 to 60 mg/d, noted that patients who responded at 3 months were more likely to be symptom-free after 1 year than those who did not respond to acute treatment.16 Responders’ mean 2-week compulsive spending declined from $773 before treatment to $351 at 12 months, and their mean total debt declined from $17,833 to $16,752.
Because remission was not significantly associated with taking citalopram, however, the authors concluded that the mechanisms responsible for maintaining remission were unclear.
Psychotherapy. Cognitive-behavioral therapy (CBT) may help, but few therapists are familiar with this disorder. CBT challenges the patient’s cognitive distortions and faulty schemas about shopping, such as:
- “Having the latest fashions will make me more popular.”
- “Having 5 pair of new shoes will make me a happier and better person.”
Our recommendations. Medication—such as an antidepressant for major depression or a mood stabilizer for bipolar disorder—may improve compulsive shopping in patients with a comorbid psychiatric disorder. For other compulsive shoppers, however, medication trials provide little guidance for treatment.
We inform patients such as Ms. A that they cannot rely on medication to control their behavior. Instead, we recommend a four-step approach to break the compulsive shopping habit (Table 3).
Financial counseling, provided free of charge by many banks, benefits some patients. Self-help books describe strategies to overcome compulsive spending (Related resources). Debtors Anonymous, a 12-step program patterned after Alcoholics Anonymous, also can help by offering acceptance, belonging, forgiveness, and understanding.
In the most severe cases we recommend appointing a financial conservator to control the patient’s finances. We rarely advise this strategy but have encountered cases in which there seemed to be no other option. Having a conservator controls the patient’s spending but does not reverse the preoccupation with shopping.
Table 3
Patient education: 4 steps to control compulsive spending
|
For clinicians
- Black DW. Assessment of compulsive buying. In: Benson AL (ed). I shop, therefore I am: Compulsive buying and the search for self. Northvale, NJ: Jason Aronson; 2000:191-216.
- Arenson G. Born to spend: how to overcome compulsive spending. Blue Ridge Summit, PA: Tab Books, 1991.
- Benson AL. Stopping Overshopping. A site for shopaholics and the people who love them. www.stoppingovershopping.com.
- Mellan O. Money harmony: resolving money conflicts in your life and relationships. New York: Walker, 2005.
Drug brand names
- Citalopram • Celexa
- Escitalopram • Lexapro
- Fluvoxamine • Luvox
Dr. Kuzma reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Black receives grant/research support or is a consultant or speaker for Forest Laboratories and Shire Pharmaceuticals
1. Lee S, Mysyk A. The medicalization of compulsive buying. Soc Sci Med 2004;58(9):1709-18.
2. Black DW. Compulsive buying disorder: definition, assessment, epidemiology and clinical management. CNS Drugs 2001;15(1):17-27.
3. Hollander E. Obsessive compulsive related disorders. Washington, DC: American Psychiatric Press; 1993.
4. Lejoyeux M, Bailly F, Moula H, Loi S, Ades J. Study of compulsive buying in patients presenting with obsessive-compulsive disorder. Compr Psychiatry 2005;46:105-10.
5. Black DW. Compulsive shopping. In: Hollander E, Stein D (eds). Clinical manual of impulse control disorders. Washington, DC: American Psychiatric Publishing; 2003;203–27.
6. Black DW, Monahan P, Schlosser S, Repertinger S. Compulsive buying severity: an analysis of Compulsive Buying Scale results in 44 subjects. J Nerv Ment Dis 2001;189:123-7.
7. McElroy SL, Keck PE, Jr, Pope HG, Jr, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry 1994;55:242-8.
8. Black DW, Repertinger S, Gaffney GR, Gabel J. Family history and psychiatric comorbidity in persons with compulsive buying: preliminary findings. Am J Psychiatry 1998;155:960-3.
9. Faber RJ, O’Guinn TC. A clinical screener for compulsive buying. Consum Res 1992;19:459-69.
10. Monahan P, Black DW, Gabel J. Reliability and validity of a scale to measure change in persons with compulsive buying. Psychiatr Res 1996;64:59-67.
11. Black DW, Monahan P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 1997;58:159-63.
12. Ninan PT, McElroy SL, Kane CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 2000;20:362-6.
13. Black DW, Gabel J, Hansen J, Schlosser S. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000;12:205-11.
14. Koran LM, Chuong HW, Bullock KD, Smith SC. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry 2003;64:793-8.
15. Koran LM. Escitalopram treatment evaluated in patients with compulsive shopping disorder. Primary Psychiatry 2005;12(12):13.-
16. Aboujaoude E, Gamel N, Koran LM. A 1-year naturalistic follow-up of patients with compulsive shopping disorder. J Clin Psychiatry 2003;64:946-50.
Ms. A has been compulsively shopping and spending since age 19 when she first obtained credit cards. After years of intense urges to shop and remorse over the financial consequences, she seeks psychiatric help. Now age 37 and divorced, she has controlled her spending only for two 1- to 2-year periods that coincided with bankruptcy proceedings.
With easy access to credit, many persons such as Ms. A develop what is variously called compulsive buying, compulsive shopping, addictive shopping, or shopaholism. Although “medicalizing” excessive shopping may seem to obscure its broader cultural and social causes,1 increasing evidence points to a discrete shopping disorder.
Our group has contributed to compulsive buying research and continues to evaluate potential treatments. We offer evidence and practical advice to help you:
- identify compulsive shopping disorder using the patient’s history and three screening questions
- differentiate compulsive shopping from manic or hypomanic shopping sprees
- educate patients about four steps to control compulsive shopping.
Table 1
Compulsive shopping disorder’s clinical signs
Onset in late adolescence to early adulthood |
Female-to-male ratio may be 9:1 |
Behaviors include shopping frequently, spending inappropriately, and fantasizing about future purchases |
Psychiatric comorbidity—mood disorders, substance abuse, eating disorders—is common among patients and first-degree relatives |
Chronic symptoms wax and wane, with widely varying severity |
Irresistible urges prompt spending by some patients |
Shopping is intensely exciting, with transitory feelings of happiness and power |
Feelings of distress and guilt develop after shopping; patients often hide purchases |
Patients may be in denial or feel embarrassed to disclose symptoms |
An Evolving Picture
Ms. A says shopping is her primary social activity and entertainment. Though she works full time, she shops three or more times a week, cruising expensive department stores and discount outlets on evenings and weekends. She buys clothing, shoes, makeup, jewelry, antiques, household electronics, and other items.
She says her shopping is spontaneous and impulsive. Shopping gives her an emotional “rush” that is frequently followed by periods of guilt, and she often returns or gives away purchased items. She is disappointed at her inability to control her shopping behavior and ashamed of the financial crises she has caused.
Compulsive buying is characterized by persistent or poorly controlled preoccupations, urges, or behaviors regarding shopping or spending, leading to adverse consequences.2 Onset in late adolescence to early adulthood is the usual pattern, and the disorder is thought to be chronic or recurrent. It is not listed in DSM-IV-TR but is considered an example of an impulse control disorder not otherwise specified. For this paper, we use the terms compulsive shopping and compulsive buying interchangeably.
The disorder’s tentative classification reflects debate about its conceptualization. Some clinicians and researchers consider compulsive buying an addiction similar to drug or alcohol misuse; others have linked it to depression or anxiety. Hollander3 and others have commented on its similarities with obsessive-compulsive disorder (OCD), and a recent study noted that compulsive buying is more common in patients with OCD than in matched controls.4 Still others—drawing on Kraepelin’s and Bleuler’s early work—consider compulsive buying an impulse control disorder, having features in common with pathological gambling and kleptomania.5
Prevalence. One survey estimates 2% to 8% of U.S. adults meet criteria for a compulsive shopping disorder, and community-based and clinical surveys suggest that 86% to 95% of them are women.5 The reported gender difference may be artifactual; women readily acknowledge that they enjoy shopping, whereas men are more likely to report that they “collect.”
Behavior patterns. No careful, longitudinal studies have examined compulsive buying disorder, but case reports suggest the condition is chronic, with a waxing and waning course and wide variance in symptom severity. In 20 consecutive patients with compulsive buying symptoms, one-half reported that irresistible urges prompted spending and three-quarters preferred to shop alone.6
Compulsive shoppers tend to shop frequently and spend inappropriately:
- at department and discount stores, specialty shops, and boutiques
- from mail order, television, and online merchants.
While shopping, compulsive shoppers may report feeling intensely excited, happy, and powerful. These emotions are frequently followed by distress or guilt. They may return purchases or hide them in closets or attics, never to be used.
Low-income persons who shop compulsively may do so at consignment shops or garage sales. In one of our studies, the most severe compulsive buyers had the lowest incomes,6 suggesting that:
- lack of money does not prevent compulsive shopping disorder from developing
- severe compulsive shoppers lack the ability to delay their shopping.
Psychiatric comorbidity
Compulsive buyers differ from matched controls when dimensional scales are used to measure psychopathology. One study found that compulsive buyers had elevated scores on the Beck Depression Inventory, the Spielberger Trait Anxiety Scale, and the Maudsley Obsessive Compulsive Inventory.2
Compulsive buyers and their first-degree relatives often have comorbid psychiatric disorders, particularly mood, anxiety, substance use, and eating disorders.5 Axis II disorders are also common; no particular type predominates, but the obsessive-compulsive, borderline, and avoidant personality types are seen most frequently.
McElroy et al7 defined compulsive buying disorder as:
- uncontrollable
- markedly distressing, time-consuming, and/or resulting in family, social, vocational, and/or financial difficulties
- not occurring only in the context of hypomanic or manic symptoms.
In a larger controlled study, our group8 compared 33 individuals who met the McElroy et al criteria for compulsive buying disorder and 22 control patients. The 137 first-degree relatives of the compulsive shoppers were significantly more likely than the controls’ relatives to have histories of depression, alcoholism, substance use, or multiple psychiatric diagnoses (as measured by the Family History Research Diagnostic Criteria).
Identifying a patient’s psychiatric comorbidities can help you develop:
- a biopsychosocial counseling plan—such as for a patient with borderline personality disorder who shops to relieve tension from relationship stress
- pharmacologic treatment strategies—such as prescribing a selective serotonin reuptake inhibitor (SSRI) for patients with comorbid major depression.
Manic versus compulsive behavior
Manic and hypomanic symptoms may be associated with impulsive and reckless spending. Thus, when evaluating excessive spending, always carefully evaluate patients for bipolar disorder.
Bipolar mania and excessive spending related to a compulsive buying disorder are relatively easy to differentiate:
- The manic patient’s unrestrained spending sprees correspond to manic episodes and are accompanied by euphoric mood, grandiosity, unrealistic plans, and often a giddy, overly bright affect.
- The compulsive shopper’s spending occurs year-round in a pattern suggesting ongoing preoccupation.
Not so for the manic, who may boast of his or her spending, display the evidence, and try to convince family and friends that the purchase is necessary or fits into some grandiose scheme. “Who doesn’t need two BMWs?” a manic patient said to one of the authors [DWB].
Screening and diagnosis
As with any psychiatric disorder, gathering an accurate history through a careful interview is important. This can be challenging with compulsive shopping disorder, however, because the patient may minimize symptoms out of embarrassment or denial. Your goal is to identify the shopping problem through nonjudgmental inquiries.
Diagnostic instruments. Researchers use assessment tools such as Faber and O’Guinn’s 7-item Compulsive Buying Scale9 to help diagnose this disorder. Our group developed a shopping version of the Yale-Brown Obsessive Compulsive Scale (YBOCS-SV) to help rate severity and change during clinical trials.10
Formal instruments may help in the clinical setting, but you can often elicit compulsive buying symptoms with a few screening questions (Table 2). If screening indicates a positive response, move to more detailed questions about:
- frequency of excessive shopping
- time spent shopping
- factors that trigger or worsen the shopping behavior
- amount of money spent.
Table 2
Is your patient a compulsive shopper? Ask these screening questions
Do you feel preoccupied with shopping and spending? |
Do you ever feel that your shopping behavior is excessive, inappropriate, or uncontrolled? |
Have your shopping desires, urges, fantasies, or behaviors ever:
|
Source: Black DW. Assessment of compulsive buying. In: Benson AL, ed. I shop, therefore I am: Compulsive buying and the search for self. Northvale, NJ: Jason Aronson; 2000:191-216. |
Stopping uncontrolled shopping
Compulsive shopping has no standard treatment, but evidence shows benefit from some SSRIs and psychotherapies.
Fluvoxamine. An early case series suggested antidepressants could curb compulsive buying,5 but later research has yielded mixed results.
Ms. A entered an experimental drug trial. She was randomly assigned to receive fluvoxamine and—despite difficulties with oversedation—tolerated a sustained dosage of 100 mg/d. After the 9-week trial, Ms. A said she thought less frequently about shopping, felt less compulsion to shop, and was spending less money and time shopping.
This open-label trial we conducted indicated that fluvoxamine, up to 300 mg/d, could be an effective treatment for compulsive buying.11 Two subsequent randomized controlled trials, however, found fluvoxamine did no better than placebo when treating compulsive shoppers.12,13
Citalopram. In an open-label trial,14 23 women and 1 man who met diagnostic criteria for compulsive shopping disorder (YBOCS-SV scores ≥17) received citalopram for 7 weeks. Dosages started at 20 mg/d and were increased as tolerated to 60 mg/d. Fifteen patients (63%) met response criteria—“much improved” or “very much improved” as measured by the Clinical Global Impressions-Improvement scale and a ≥50% decrease in YBOCS-SV score. Three patients (13%) discontinued treatment because of adverse effects (headache, rash, insomnia).
The 15 responders were then enrolled in a 9-week double-blind, placebo-controlled trial. Compulsive shopping symptoms recurred in 5 of 8 patients (63%) assigned to placebo, compared with none of the 7 who continued taking citalopram.
By comparison, escitalopram, 10 to 20 mg/d, showed little effect for compulsive shopping symptoms in an identically designed discontinuation trial by the same investigators. During the 7-week, open-label trial, 19 of 26 patients met response criteria. In the 9-week double-blind, controlled phase, however, 63% of initial responders relapsed while taking escitalopram, compared with 67% of those randomized to placebo.15
A naturalistic follow-up study of 24 patients treated with citalopram, 20 to 60 mg/d, noted that patients who responded at 3 months were more likely to be symptom-free after 1 year than those who did not respond to acute treatment.16 Responders’ mean 2-week compulsive spending declined from $773 before treatment to $351 at 12 months, and their mean total debt declined from $17,833 to $16,752.
Because remission was not significantly associated with taking citalopram, however, the authors concluded that the mechanisms responsible for maintaining remission were unclear.
Psychotherapy. Cognitive-behavioral therapy (CBT) may help, but few therapists are familiar with this disorder. CBT challenges the patient’s cognitive distortions and faulty schemas about shopping, such as:
- “Having the latest fashions will make me more popular.”
- “Having 5 pair of new shoes will make me a happier and better person.”
Our recommendations. Medication—such as an antidepressant for major depression or a mood stabilizer for bipolar disorder—may improve compulsive shopping in patients with a comorbid psychiatric disorder. For other compulsive shoppers, however, medication trials provide little guidance for treatment.
We inform patients such as Ms. A that they cannot rely on medication to control their behavior. Instead, we recommend a four-step approach to break the compulsive shopping habit (Table 3).
Financial counseling, provided free of charge by many banks, benefits some patients. Self-help books describe strategies to overcome compulsive spending (Related resources). Debtors Anonymous, a 12-step program patterned after Alcoholics Anonymous, also can help by offering acceptance, belonging, forgiveness, and understanding.
In the most severe cases we recommend appointing a financial conservator to control the patient’s finances. We rarely advise this strategy but have encountered cases in which there seemed to be no other option. Having a conservator controls the patient’s spending but does not reverse the preoccupation with shopping.
Table 3
Patient education: 4 steps to control compulsive spending
|
For clinicians
- Black DW. Assessment of compulsive buying. In: Benson AL (ed). I shop, therefore I am: Compulsive buying and the search for self. Northvale, NJ: Jason Aronson; 2000:191-216.
- Arenson G. Born to spend: how to overcome compulsive spending. Blue Ridge Summit, PA: Tab Books, 1991.
- Benson AL. Stopping Overshopping. A site for shopaholics and the people who love them. www.stoppingovershopping.com.
- Mellan O. Money harmony: resolving money conflicts in your life and relationships. New York: Walker, 2005.
Drug brand names
- Citalopram • Celexa
- Escitalopram • Lexapro
- Fluvoxamine • Luvox
Dr. Kuzma reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Black receives grant/research support or is a consultant or speaker for Forest Laboratories and Shire Pharmaceuticals
Ms. A has been compulsively shopping and spending since age 19 when she first obtained credit cards. After years of intense urges to shop and remorse over the financial consequences, she seeks psychiatric help. Now age 37 and divorced, she has controlled her spending only for two 1- to 2-year periods that coincided with bankruptcy proceedings.
With easy access to credit, many persons such as Ms. A develop what is variously called compulsive buying, compulsive shopping, addictive shopping, or shopaholism. Although “medicalizing” excessive shopping may seem to obscure its broader cultural and social causes,1 increasing evidence points to a discrete shopping disorder.
Our group has contributed to compulsive buying research and continues to evaluate potential treatments. We offer evidence and practical advice to help you:
- identify compulsive shopping disorder using the patient’s history and three screening questions
- differentiate compulsive shopping from manic or hypomanic shopping sprees
- educate patients about four steps to control compulsive shopping.
Table 1
Compulsive shopping disorder’s clinical signs
Onset in late adolescence to early adulthood |
Female-to-male ratio may be 9:1 |
Behaviors include shopping frequently, spending inappropriately, and fantasizing about future purchases |
Psychiatric comorbidity—mood disorders, substance abuse, eating disorders—is common among patients and first-degree relatives |
Chronic symptoms wax and wane, with widely varying severity |
Irresistible urges prompt spending by some patients |
Shopping is intensely exciting, with transitory feelings of happiness and power |
Feelings of distress and guilt develop after shopping; patients often hide purchases |
Patients may be in denial or feel embarrassed to disclose symptoms |
An Evolving Picture
Ms. A says shopping is her primary social activity and entertainment. Though she works full time, she shops three or more times a week, cruising expensive department stores and discount outlets on evenings and weekends. She buys clothing, shoes, makeup, jewelry, antiques, household electronics, and other items.
She says her shopping is spontaneous and impulsive. Shopping gives her an emotional “rush” that is frequently followed by periods of guilt, and she often returns or gives away purchased items. She is disappointed at her inability to control her shopping behavior and ashamed of the financial crises she has caused.
Compulsive buying is characterized by persistent or poorly controlled preoccupations, urges, or behaviors regarding shopping or spending, leading to adverse consequences.2 Onset in late adolescence to early adulthood is the usual pattern, and the disorder is thought to be chronic or recurrent. It is not listed in DSM-IV-TR but is considered an example of an impulse control disorder not otherwise specified. For this paper, we use the terms compulsive shopping and compulsive buying interchangeably.
The disorder’s tentative classification reflects debate about its conceptualization. Some clinicians and researchers consider compulsive buying an addiction similar to drug or alcohol misuse; others have linked it to depression or anxiety. Hollander3 and others have commented on its similarities with obsessive-compulsive disorder (OCD), and a recent study noted that compulsive buying is more common in patients with OCD than in matched controls.4 Still others—drawing on Kraepelin’s and Bleuler’s early work—consider compulsive buying an impulse control disorder, having features in common with pathological gambling and kleptomania.5
Prevalence. One survey estimates 2% to 8% of U.S. adults meet criteria for a compulsive shopping disorder, and community-based and clinical surveys suggest that 86% to 95% of them are women.5 The reported gender difference may be artifactual; women readily acknowledge that they enjoy shopping, whereas men are more likely to report that they “collect.”
Behavior patterns. No careful, longitudinal studies have examined compulsive buying disorder, but case reports suggest the condition is chronic, with a waxing and waning course and wide variance in symptom severity. In 20 consecutive patients with compulsive buying symptoms, one-half reported that irresistible urges prompted spending and three-quarters preferred to shop alone.6
Compulsive shoppers tend to shop frequently and spend inappropriately:
- at department and discount stores, specialty shops, and boutiques
- from mail order, television, and online merchants.
While shopping, compulsive shoppers may report feeling intensely excited, happy, and powerful. These emotions are frequently followed by distress or guilt. They may return purchases or hide them in closets or attics, never to be used.
Low-income persons who shop compulsively may do so at consignment shops or garage sales. In one of our studies, the most severe compulsive buyers had the lowest incomes,6 suggesting that:
- lack of money does not prevent compulsive shopping disorder from developing
- severe compulsive shoppers lack the ability to delay their shopping.
Psychiatric comorbidity
Compulsive buyers differ from matched controls when dimensional scales are used to measure psychopathology. One study found that compulsive buyers had elevated scores on the Beck Depression Inventory, the Spielberger Trait Anxiety Scale, and the Maudsley Obsessive Compulsive Inventory.2
Compulsive buyers and their first-degree relatives often have comorbid psychiatric disorders, particularly mood, anxiety, substance use, and eating disorders.5 Axis II disorders are also common; no particular type predominates, but the obsessive-compulsive, borderline, and avoidant personality types are seen most frequently.
McElroy et al7 defined compulsive buying disorder as:
- uncontrollable
- markedly distressing, time-consuming, and/or resulting in family, social, vocational, and/or financial difficulties
- not occurring only in the context of hypomanic or manic symptoms.
In a larger controlled study, our group8 compared 33 individuals who met the McElroy et al criteria for compulsive buying disorder and 22 control patients. The 137 first-degree relatives of the compulsive shoppers were significantly more likely than the controls’ relatives to have histories of depression, alcoholism, substance use, or multiple psychiatric diagnoses (as measured by the Family History Research Diagnostic Criteria).
Identifying a patient’s psychiatric comorbidities can help you develop:
- a biopsychosocial counseling plan—such as for a patient with borderline personality disorder who shops to relieve tension from relationship stress
- pharmacologic treatment strategies—such as prescribing a selective serotonin reuptake inhibitor (SSRI) for patients with comorbid major depression.
Manic versus compulsive behavior
Manic and hypomanic symptoms may be associated with impulsive and reckless spending. Thus, when evaluating excessive spending, always carefully evaluate patients for bipolar disorder.
Bipolar mania and excessive spending related to a compulsive buying disorder are relatively easy to differentiate:
- The manic patient’s unrestrained spending sprees correspond to manic episodes and are accompanied by euphoric mood, grandiosity, unrealistic plans, and often a giddy, overly bright affect.
- The compulsive shopper’s spending occurs year-round in a pattern suggesting ongoing preoccupation.
Not so for the manic, who may boast of his or her spending, display the evidence, and try to convince family and friends that the purchase is necessary or fits into some grandiose scheme. “Who doesn’t need two BMWs?” a manic patient said to one of the authors [DWB].
Screening and diagnosis
As with any psychiatric disorder, gathering an accurate history through a careful interview is important. This can be challenging with compulsive shopping disorder, however, because the patient may minimize symptoms out of embarrassment or denial. Your goal is to identify the shopping problem through nonjudgmental inquiries.
Diagnostic instruments. Researchers use assessment tools such as Faber and O’Guinn’s 7-item Compulsive Buying Scale9 to help diagnose this disorder. Our group developed a shopping version of the Yale-Brown Obsessive Compulsive Scale (YBOCS-SV) to help rate severity and change during clinical trials.10
Formal instruments may help in the clinical setting, but you can often elicit compulsive buying symptoms with a few screening questions (Table 2). If screening indicates a positive response, move to more detailed questions about:
- frequency of excessive shopping
- time spent shopping
- factors that trigger or worsen the shopping behavior
- amount of money spent.
Table 2
Is your patient a compulsive shopper? Ask these screening questions
Do you feel preoccupied with shopping and spending? |
Do you ever feel that your shopping behavior is excessive, inappropriate, or uncontrolled? |
Have your shopping desires, urges, fantasies, or behaviors ever:
|
Source: Black DW. Assessment of compulsive buying. In: Benson AL, ed. I shop, therefore I am: Compulsive buying and the search for self. Northvale, NJ: Jason Aronson; 2000:191-216. |
Stopping uncontrolled shopping
Compulsive shopping has no standard treatment, but evidence shows benefit from some SSRIs and psychotherapies.
Fluvoxamine. An early case series suggested antidepressants could curb compulsive buying,5 but later research has yielded mixed results.
Ms. A entered an experimental drug trial. She was randomly assigned to receive fluvoxamine and—despite difficulties with oversedation—tolerated a sustained dosage of 100 mg/d. After the 9-week trial, Ms. A said she thought less frequently about shopping, felt less compulsion to shop, and was spending less money and time shopping.
This open-label trial we conducted indicated that fluvoxamine, up to 300 mg/d, could be an effective treatment for compulsive buying.11 Two subsequent randomized controlled trials, however, found fluvoxamine did no better than placebo when treating compulsive shoppers.12,13
Citalopram. In an open-label trial,14 23 women and 1 man who met diagnostic criteria for compulsive shopping disorder (YBOCS-SV scores ≥17) received citalopram for 7 weeks. Dosages started at 20 mg/d and were increased as tolerated to 60 mg/d. Fifteen patients (63%) met response criteria—“much improved” or “very much improved” as measured by the Clinical Global Impressions-Improvement scale and a ≥50% decrease in YBOCS-SV score. Three patients (13%) discontinued treatment because of adverse effects (headache, rash, insomnia).
The 15 responders were then enrolled in a 9-week double-blind, placebo-controlled trial. Compulsive shopping symptoms recurred in 5 of 8 patients (63%) assigned to placebo, compared with none of the 7 who continued taking citalopram.
By comparison, escitalopram, 10 to 20 mg/d, showed little effect for compulsive shopping symptoms in an identically designed discontinuation trial by the same investigators. During the 7-week, open-label trial, 19 of 26 patients met response criteria. In the 9-week double-blind, controlled phase, however, 63% of initial responders relapsed while taking escitalopram, compared with 67% of those randomized to placebo.15
A naturalistic follow-up study of 24 patients treated with citalopram, 20 to 60 mg/d, noted that patients who responded at 3 months were more likely to be symptom-free after 1 year than those who did not respond to acute treatment.16 Responders’ mean 2-week compulsive spending declined from $773 before treatment to $351 at 12 months, and their mean total debt declined from $17,833 to $16,752.
Because remission was not significantly associated with taking citalopram, however, the authors concluded that the mechanisms responsible for maintaining remission were unclear.
Psychotherapy. Cognitive-behavioral therapy (CBT) may help, but few therapists are familiar with this disorder. CBT challenges the patient’s cognitive distortions and faulty schemas about shopping, such as:
- “Having the latest fashions will make me more popular.”
- “Having 5 pair of new shoes will make me a happier and better person.”
Our recommendations. Medication—such as an antidepressant for major depression or a mood stabilizer for bipolar disorder—may improve compulsive shopping in patients with a comorbid psychiatric disorder. For other compulsive shoppers, however, medication trials provide little guidance for treatment.
We inform patients such as Ms. A that they cannot rely on medication to control their behavior. Instead, we recommend a four-step approach to break the compulsive shopping habit (Table 3).
Financial counseling, provided free of charge by many banks, benefits some patients. Self-help books describe strategies to overcome compulsive spending (Related resources). Debtors Anonymous, a 12-step program patterned after Alcoholics Anonymous, also can help by offering acceptance, belonging, forgiveness, and understanding.
In the most severe cases we recommend appointing a financial conservator to control the patient’s finances. We rarely advise this strategy but have encountered cases in which there seemed to be no other option. Having a conservator controls the patient’s spending but does not reverse the preoccupation with shopping.
Table 3
Patient education: 4 steps to control compulsive spending
|
For clinicians
- Black DW. Assessment of compulsive buying. In: Benson AL (ed). I shop, therefore I am: Compulsive buying and the search for self. Northvale, NJ: Jason Aronson; 2000:191-216.
- Arenson G. Born to spend: how to overcome compulsive spending. Blue Ridge Summit, PA: Tab Books, 1991.
- Benson AL. Stopping Overshopping. A site for shopaholics and the people who love them. www.stoppingovershopping.com.
- Mellan O. Money harmony: resolving money conflicts in your life and relationships. New York: Walker, 2005.
Drug brand names
- Citalopram • Celexa
- Escitalopram • Lexapro
- Fluvoxamine • Luvox
Dr. Kuzma reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
Dr. Black receives grant/research support or is a consultant or speaker for Forest Laboratories and Shire Pharmaceuticals
1. Lee S, Mysyk A. The medicalization of compulsive buying. Soc Sci Med 2004;58(9):1709-18.
2. Black DW. Compulsive buying disorder: definition, assessment, epidemiology and clinical management. CNS Drugs 2001;15(1):17-27.
3. Hollander E. Obsessive compulsive related disorders. Washington, DC: American Psychiatric Press; 1993.
4. Lejoyeux M, Bailly F, Moula H, Loi S, Ades J. Study of compulsive buying in patients presenting with obsessive-compulsive disorder. Compr Psychiatry 2005;46:105-10.
5. Black DW. Compulsive shopping. In: Hollander E, Stein D (eds). Clinical manual of impulse control disorders. Washington, DC: American Psychiatric Publishing; 2003;203–27.
6. Black DW, Monahan P, Schlosser S, Repertinger S. Compulsive buying severity: an analysis of Compulsive Buying Scale results in 44 subjects. J Nerv Ment Dis 2001;189:123-7.
7. McElroy SL, Keck PE, Jr, Pope HG, Jr, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry 1994;55:242-8.
8. Black DW, Repertinger S, Gaffney GR, Gabel J. Family history and psychiatric comorbidity in persons with compulsive buying: preliminary findings. Am J Psychiatry 1998;155:960-3.
9. Faber RJ, O’Guinn TC. A clinical screener for compulsive buying. Consum Res 1992;19:459-69.
10. Monahan P, Black DW, Gabel J. Reliability and validity of a scale to measure change in persons with compulsive buying. Psychiatr Res 1996;64:59-67.
11. Black DW, Monahan P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 1997;58:159-63.
12. Ninan PT, McElroy SL, Kane CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 2000;20:362-6.
13. Black DW, Gabel J, Hansen J, Schlosser S. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000;12:205-11.
14. Koran LM, Chuong HW, Bullock KD, Smith SC. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry 2003;64:793-8.
15. Koran LM. Escitalopram treatment evaluated in patients with compulsive shopping disorder. Primary Psychiatry 2005;12(12):13.-
16. Aboujaoude E, Gamel N, Koran LM. A 1-year naturalistic follow-up of patients with compulsive shopping disorder. J Clin Psychiatry 2003;64:946-50.
1. Lee S, Mysyk A. The medicalization of compulsive buying. Soc Sci Med 2004;58(9):1709-18.
2. Black DW. Compulsive buying disorder: definition, assessment, epidemiology and clinical management. CNS Drugs 2001;15(1):17-27.
3. Hollander E. Obsessive compulsive related disorders. Washington, DC: American Psychiatric Press; 1993.
4. Lejoyeux M, Bailly F, Moula H, Loi S, Ades J. Study of compulsive buying in patients presenting with obsessive-compulsive disorder. Compr Psychiatry 2005;46:105-10.
5. Black DW. Compulsive shopping. In: Hollander E, Stein D (eds). Clinical manual of impulse control disorders. Washington, DC: American Psychiatric Publishing; 2003;203–27.
6. Black DW, Monahan P, Schlosser S, Repertinger S. Compulsive buying severity: an analysis of Compulsive Buying Scale results in 44 subjects. J Nerv Ment Dis 2001;189:123-7.
7. McElroy SL, Keck PE, Jr, Pope HG, Jr, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry 1994;55:242-8.
8. Black DW, Repertinger S, Gaffney GR, Gabel J. Family history and psychiatric comorbidity in persons with compulsive buying: preliminary findings. Am J Psychiatry 1998;155:960-3.
9. Faber RJ, O’Guinn TC. A clinical screener for compulsive buying. Consum Res 1992;19:459-69.
10. Monahan P, Black DW, Gabel J. Reliability and validity of a scale to measure change in persons with compulsive buying. Psychiatr Res 1996;64:59-67.
11. Black DW, Monahan P, Gabel J. Fluvoxamine in the treatment of compulsive buying. J Clin Psychiatry 1997;58:159-63.
12. Ninan PT, McElroy SL, Kane CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 2000;20:362-6.
13. Black DW, Gabel J, Hansen J, Schlosser S. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000;12:205-11.
14. Koran LM, Chuong HW, Bullock KD, Smith SC. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry 2003;64:793-8.
15. Koran LM. Escitalopram treatment evaluated in patients with compulsive shopping disorder. Primary Psychiatry 2005;12(12):13.-
16. Aboujaoude E, Gamel N, Koran LM. A 1-year naturalistic follow-up of patients with compulsive shopping disorder. J Clin Psychiatry 2003;64:946-50.